Skip to main content
. 2012 Mar;7(3):504–512. doi: 10.2215/CJN.06940711

Figure 2.

Figure 2.

Cumulative patient survival, renal allograft survival, and rejection-free survival in tacrolimus/mycophenolate mofetil (Tac/MMF) and Tac/sirolimus (Tac/SRL) groups. Kaplan–Meier patient survival curves. Log-rank test (A, P=0.05; B, P=0.01; C, P=0.08). *Numbers at risk in each group.